jm + pembro   1

‘This is not the end’: Using immunotherapy to target genes gives cancer patients hope - The Washington Post
Pembrolizumab, marketed by Merck as Keytruda, is an anti-PD-1 immunotherapy drug now going through US trials, targeting malignancies with certain molecular characteristics.

Good trial results vs melanoma here:
cancer  trials  drugs  pembro  anti-pd-1  immunotherapy  merck 
may 2017 by jm

Copy this bookmark: